Pipeline | AbbVie - Pharmaceutical Research & Development
WEBABBV-706 is a seizure protein 6 homolog (SEZ6) targeted antibody-drug conjugate being investigated for the treatment of small cell lung cancer, central nervous system tumors and neuroendocrine carcinomas.
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New …
WEBMay 28, 2024 · AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform. New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC.
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) …
WEBJan 9, 2024 · PRODUODOPA ® (foslevodopa/foscarbidopa) is a solution of levodopa and carbidopa prodrugs for 24-hour continuous subcutaneous infusion for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal …
AbbVie Provides U.S. Regulatory Update on ABBV-951 …
WEBNORTH CHICAGO, Ill., June 25, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with …
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New …
WEBMay 28, 2024 · AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society...
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) …
WEBJan 9, 2024 · The Phase 3 randomized, double-blind, double-dummy, active-controlled study compared the efficacy, safety and tolerability of PRODUODOPA to oral immediate-release levodopa/carbidopa (LD/CD) in ...
AbbVie Provides Regulatory Update on ABBV-951 …
WEBMar 22, 2023 · AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with...
Pharmaceutical Research & Development | AbbVie
WEBOct 28, 2021 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
AbbVie Submits New Drug Application to U.S. FDA for …
WEBMay 20, 2022 · ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of motor fluctuations in...
AbbVie Receives Positive CHMP Opinion for Mirvetuximab …
WEB2 days ago · NORTH CHICAGO, Ill., Sept. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted ...